Maria Hatzipanagiotou, Dana Holzinger, Françoise Millogo, Michael Pawlita, Jürgen Wacker
Department of Gynecology and Obstetrics, Caritas-Krankenhaus St. Josef, University Medical Center Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany.
Research Program Infection and Cancer, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 242, 69120, Heidelberg, Germany.
Arch Gynecol Obstet. 2018 Oct;298(4):789-796. doi: 10.1007/s00404-018-4860-z. Epub 2018 Aug 17.
Cervical cancer is the most common cancer in women in low income countries. Certain oncogenic types of human papillomaviruses are causally associated with the cervical cancer. To ensure effective primary prevention through the introduction of a national vaccination program in Burkina Faso, information about the disease burden of HPV infection in the country is of great importance.
In the present work the prevalence of 54 different HPV types and 18 other sexually transmitted infection as well as the predominant risk factors for the development of cervical cancer were investigated in Ouagadougou. A cross-sectional study on two populations without (n=471) and with known cervical dysplasia (n=39) was carried out between October 2013 and March 2014. Retrospectively, data on possible and secured risk factors of the cervical carcinoma were collected. The participants were examined gynecologically and a vaginal lavage was taken, which was molecular genetically examined for 54 different human papillomavirus genotypes and 18 other STIs.
The prevalence of human papillomavirus was 42.3% (188/444) in the first study population and 87.2% (34/39) in the second study population. The immunization coverage would be 24.5% of the HPV types and 33.9% of the high-risk HPV types with quadrivalent vaccine Gardasil®. The nonavalent vaccine Gardasil®9 (9vHPV) would cover 37.3% of all HPV types and 57.1% of high-risk HPV types.
The prevention of infection with human papillomaviruses by vaccination is expected to result in a drastic reduction in the morbidity and mortality of the cervical cancer in Burkina Faso.
宫颈癌是低收入国家女性中最常见的癌症。某些致癌型人乳头瘤病毒与宫颈癌存在因果关联。为通过在布基纳法索推行国家疫苗接种计划确保有效的一级预防，了解该国HPV感染的疾病负担至关重要。
在本研究中，于瓦加杜古对54种不同HPV类型和18种其他性传播感染的流行情况以及宫颈癌发生的主要危险因素进行了调查。2013年10月至2014年3月期间，对两组人群开展了横断面研究，一组为无宫颈发育异常者（n = 471），另一组为已知宫颈发育异常者（n = 39）。回顾性收集了宫颈癌可能的和确定的危险因素的数据。对参与者进行妇科检查并采集阴道灌洗液，对其进行分子遗传学检测，以确定54种不同的人乳头瘤病毒基因型和18种其他性传播感染。
在第一个研究人群中，人乳头瘤病毒的流行率为42.3%（188/444），在第二个研究人群中为87.2%（34/39）。四价疫苗佳达修（Gardasil®）对HPV类型的免疫覆盖率为24.5%，对高危HPV类型的免疫覆盖率为33.9%。九价疫苗佳达修9（Gardasil®9，9vHPV）将覆盖所有HPV类型的37.3%和高危HPV类型的57.1%。
通过接种疫苗预防人乳头瘤病毒感染有望大幅降低布基纳法索宫颈癌的发病率和死亡率。
